A 50 year-old woman with HCV-related chronic hepatitis, without history of psoriasis, had been previously treated with 2 cycles of IFN: firstly she had received recombinant IFN alpha α2b (Intron A®, Schering-Plough) 3 MU trice/week for 36 weeks (September 1996–May 1997); then Lymphoblastoid IFN (Wellferon®, Glaxo Wellcome) 3 MU trice/week for 24 weeks (October 1997–March 1998). This evidence concerns the gene IFNA1 and chronic hepatitis.